By representing perspectives from the entire cancer care team, collaboration with interprofessional colleagues is one way for oncology nurses to influence the delivery of high-quality patient care.

Confounding researchers and clinicians alike, colorectal cancer rates are dramatically increasing among younger populations. In the latest study results published in Gastroentrology, researchers quantified the drastic shift of colorectal cancer diagnoses in various young groups aged 10–24 years.

The journey from cancer diagnosis to treatment with hematopoietic stem cell transplantation (HSCT) is a complex, costly, and multifaceted process influenced by various factors that shape the course of patient care. HSCT is particularly susceptible to racial, socioeconomic, and geographic disparities in access and outcomes, given its specialized nature and limited availability in just about 200 U.S. cancer centers.

On June 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda^®) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.

Medicine marked a major milestone in April 2024, the U.S. Food and Drug Administration (FDA) said, when the agency announced it had approved its 50th biosimilar medication. Trastuzumab-strf, a biosimilar to the antineoplastic trastuzumab, had the honor of being the agency's 50th approval.

Merkel cell carcinoma (MCC) is a rare but aggressive form of skin cancer—although it is 40 times rarer than melanoma, it is 3–5 times more lethal. Approximately 3,000 new cases of Merkel cell carcinoma are diagnosed every year in the United States, but its incidence is increasing because of enhanced diagnostic techniques and the prevalence of risk factors.

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto^®) for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi^®) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).

The risk of dying from cancer has steadily declined in the United States over the past few decades, but Black individuals assigned female at birth still have some of the lowest survival rates. Although Black females are less likely to be diagnosed with cancer than White females, they are they more likely to die from it within five years, according to the National Cancer Institute. The disparity is particularly stark for breast cancer, which kills Black females at a 40% higher rate than White females, even though their rate of diagnosis is 4% lower.

On June 13, 2024, the U.S. Food and Drug Administration granted accelerated approval to repotrectinib (Augtyro^™) for adult and pediatric patients aged 12 and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.